PMC:7166305 / 5634-7794
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T22 | 90-97 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T23 | 159-172 | Body_part | denotes | interleukin-6 | http://purl.org/sig/ont/fma/fma264829 |
| T24 | 276-281 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T25 | 317-322 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T26 | 730-741 | Body_part | denotes | lymphocytes | http://purl.org/sig/ont/fma/fma62863 |
| T27 | 743-745 | Body_part | denotes | LY | http://purl.org/sig/ont/fma/fma62863 |
| T28 | 1505-1510 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T29 | 1592-1597 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T30 | 1679-1684 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T31 | 1849-1854 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T32 | 1939-1944 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T43 | 565-574 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T44 | 820-829 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T45 | 893-902 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T46 | 1128-1139 | Disease | denotes | lymphopenia | http://purl.obolibrary.org/obo/MONDO_0003783 |
| T47 | 1208-1216 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T43 | 130-132 | http://purl.obolibrary.org/obo/CLO_0001313 | denotes | 36 |
| T44 | 159-172 | http://purl.obolibrary.org/obo/PR_000001393 | denotes | interleukin-6 |
| T45 | 208-210 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T46 | 216-218 | http://purl.obolibrary.org/obo/CLO_0008426 | denotes | pg |
| T47 | 255-258 | http://purl.obolibrary.org/obo/CLO_0053438 | denotes | CD8 |
| T48 | 274-281 | http://purl.obolibrary.org/obo/CL_0000084 | denotes | T cells |
| T49 | 317-322 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T50 | 605-607 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
| T51 | 650-652 | http://purl.obolibrary.org/obo/CLO_0053799 | denotes | 45 |
| T52 | 711-713 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
| T53 | 847-848 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T54 | 1044-1046 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
| T55 | 1088-1089 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T56 | 1173-1175 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
| T57 | 1198-1203 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T58 | 1278-1283 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T59 | 1369-1371 | http://purl.obolibrary.org/obo/CLO_0008426 | denotes | pg |
| T60 | 1404-1406 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T61 | 1456-1458 | http://purl.obolibrary.org/obo/CLO_0053799 | denotes | 45 |
| T62 | 1470-1472 | http://purl.obolibrary.org/obo/CLO_0001313 | denotes | 36 |
| T63 | 1499-1502 | http://purl.obolibrary.org/obo/CLO_0052882 | denotes | CD3 |
| T64 | 1499-1502 | http://purl.obolibrary.org/obo/CLO_0053434 | denotes | CD3 |
| T65 | 1505-1510 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T66 | 1532-1535 | http://purl.obolibrary.org/obo/CLO_0001180 | denotes | 203 |
| T67 | 1563-1566 | http://purl.obolibrary.org/obo/CLO_0001203 | denotes | 232 |
| T68 | 1586-1589 | http://purl.obolibrary.org/obo/PR_000001004 | denotes | CD4 |
| T69 | 1592-1597 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T70 | 1673-1676 | http://purl.obolibrary.org/obo/CLO_0053438 | denotes | CD8 |
| T71 | 1679-1684 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T72 | 1757-1760 | http://purl.obolibrary.org/obo/PR_000001004 | denotes | CD4 |
| T73 | 1762-1765 | http://purl.obolibrary.org/obo/CLO_0053438 | denotes | CD8 |
| T74 | 1842-1846 | http://purl.obolibrary.org/obo/CLO_0053432 | denotes | CD19 |
| T75 | 1849-1854 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T76 | 1909-1911 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
| T77 | 1939-1944 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T78 | 2100-2101 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T79 | 2117-2121 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T32 | 90-97 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T33 | 174-176 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T35 | 743-745 | Chemical | denotes | LY | http://purl.obolibrary.org/obo/CHEBI_73591 |
| T36 | 1363-1365 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T38 | 2041-2046 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T39 | 2070-2075 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T75 | 0-415 | Sentence | denotes | In the stage of disease progression, there were significantly higher levels of C-reactive protein (CRP) (78 (28–134) versus 15 (7–36), in mg/L, p = 0.042) and interleukin-6 (IL-6) (195 (127–280) versus 12 (4–18), in pg/ml, p < 0.001), but lower levels of CD8+ subpopulation T cells (33 (23–135) versus 273 (122–377), cells/μl, p = 0.016) in non-surviving patients as compared with the patients survived (Table 1b ). |
| T76 | 416-575 | Sentence | denotes | Furthermore, in surviving patients, increases in levels of high-sensitivity CRP (hsCRP) were significantly associated with the disease severity (pre-infection: |
| T77 | 576-604 | Sentence | denotes | 1.2 (0.7–5.9); on admission: |
| T78 | 605-640 | Sentence | denotes | 11 (5.9–26), p < 0.02; progression: |
| T79 | 641-665 | Sentence | denotes | 9.8 (5.3–45); discharge: |
| T80 | 666-715 | Sentence | denotes | 2.2 (1.2–7.0), in mg/L) (Supplementary Table S1). |
| T81 | 716-903 | Sentence | denotes | The number of lymphocytes (LY) decreased significantly at the time of admission as compared with before infection; it did not show a full recovery at the time of discharge (pre-infection: |
| T82 | 904-932 | Sentence | denotes | 1.6 (1.4–2.2); on admission: |
| T83 | 933-970 | Sentence | denotes | 1.0 (0.8–1.5), p < 0.02; progression: |
| T84 | 971-996 | Sentence | denotes | 0.9 (0.5–1.4); discharge: |
| T85 | 997-1048 | Sentence | denotes | 1.2 (0.8–1.9), in x109/L) (Supplementary Table S1). |
| T86 | 1049-1177 | Sentence | denotes | In patients did not survive, there was a continuous increase in hsCRP level or lymphopenia until death (Supplementary Table S1). |
| T87 | 1178-1266 | Sentence | denotes | Table 1b Laboratory tests for COVID-19 patients during the stage of disease progression. |
| T88 | 1267-1307 | Sentence | denotes | Laboratory tests Reference value No. (%) |
| T89 | 1308-1362 | Sentence | denotes | Total (n = 21) Survival (n = 17) Non-survival(n = 4) p |
| T90 | 1363-1435 | Sentence | denotes | IL-6 (pg/ml) 0.1–2.9 15 (8–79, 19) 12 (4–18, 15) 195 (127–280, 4) <0.001 |
| T91 | 1436-1498 | Sentence | denotes | CRP (mg/L) <4 20 (7–45, 21) 15 (7–36, 17) 78 (28–134, 4) 0.042 |
| T92 | 1499-1585 | Sentence | denotes | CD3+ (cells/μl) 805 to 4459 562 (203–939, 19) 680 (303–945, 15) 232 (129–340, 4) 0.062 |
| T93 | 1586-1672 | Sentence | denotes | CD4+ (cells/μl) 345 to 2350 297 (135–557, 19) 416 (172–557, 15) 168 (108–250, 4) 0.121 |
| T94 | 1673-1756 | Sentence | denotes | CD8+ (cells/μl) 345 to 2350 166 (50–336, 19) 273 (122–377, 15) 33 (23–135, 4) 0.016 |
| T95 | 1757-1841 | Sentence | denotes | CD4+/CD8+ ratio 0.96–2.05 1.7 (1.2–3.1, 19) 1.6 (1.3–2.4, 15) 5.0 (2.0–6.2, 4) 0.079 |
| T96 | 1842-1925 | Sentence | denotes | CD19+ (cells/μl) 240 to 1317 104 (49–174, 19) 104 (49–236, 15) 84 (34–134, 4) 0.650 |
| T97 | 1926-2016 | Sentence | denotes | CD16+/CD56+ (cells/μl) 210 to 1514 164 (49–252, 19) 168 (106–252, 15) 33 (10–223, 4) 0.124 |
| T98 | 2017-2122 | Sentence | denotes | P value is compared the group that survived with the group that did not survive by a Mann-Whitney U test. |
| T99 | 2123-2160 | Sentence | denotes | Data is presented as median (IQR, n). |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T21 | 1128-1139 | Phenotype | denotes | lymphopenia | http://purl.obolibrary.org/obo/HP_0001888 |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T62 | 79-97 | PR:000005897 | denotes | C-reactive protein |
| T63 | 159-172 | PR:000001393 | denotes | interleukin-6 |
| T64 | 174-178 | PR:000001393 | denotes | IL-6 |
| T65 | 730-741 | CL:0000542 | denotes | lymphocytes |
| T66 | 1146-1151 | GO:0016265 | denotes | death |
| T67 | 1208-1216 | SP_7 | denotes | COVID-19 |
| T68 | 1365-1367 | PR:Q84LH8 | denotes | -6 |
| T69 | 1922-1930 | PR:000001483 | denotes | 650 CD16 |
| T70 | 1932-1936 | PR:000001024 | denotes | CD56 |
| T23504 | 204-206 | PR:Q84LH8 | denotes | ( |
| T9285 | 720-728 | PR:000001483 | denotes | number o |
| T21132 | 730-734 | PR:000001024 | denotes | lymp |
| T71 | 983-991 | SP_7 | denotes | ); disch |
| T24283 | 1208-1213 | UBERON:0001977 | denotes | COVID |
| T55143 | 1214-1218 | CHEBI:18059;CHEBI:18059 | denotes | 19 p |
| T37903 | 1283-1293 | SP_7 | denotes | Reference |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 162 | 1363-1367 | Gene | denotes | IL-6 | Gene:3569 |
| 163 | 1586-1589 | Gene | denotes | CD4 | Gene:920 |
| 164 | 1673-1676 | Gene | denotes | CD8 | Gene:925 |
| 165 | 1757-1760 | Gene | denotes | CD4 | Gene:920 |
| 166 | 1762-1765 | Gene | denotes | CD8 | Gene:925 |
| 167 | 1436-1439 | Gene | denotes | CRP | Gene:1401 |
| 170 | 1217-1225 | Species | denotes | patients | Tax:9606 |
| 171 | 1208-1216 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 186 | 79-97 | Gene | denotes | C-reactive protein | Gene:1401 |
| 187 | 99-102 | Gene | denotes | CRP | Gene:1401 |
| 188 | 159-172 | Gene | denotes | interleukin-6 | Gene:3569 |
| 189 | 174-178 | Gene | denotes | IL-6 | Gene:3569 |
| 190 | 255-258 | Gene | denotes | CD8 | Gene:925 |
| 191 | 355-363 | Species | denotes | patients | Tax:9606 |
| 192 | 385-393 | Species | denotes | patients | Tax:9606 |
| 193 | 442-450 | Species | denotes | patients | Tax:9606 |
| 194 | 1052-1060 | Species | denotes | patients | Tax:9606 |
| 195 | 565-574 | Disease | denotes | infection | MESH:D007239 |
| 196 | 820-829 | Disease | denotes | infection | MESH:D007239 |
| 197 | 893-902 | Disease | denotes | infection | MESH:D007239 |
| 198 | 1128-1139 | Disease | denotes | lymphopenia | MESH:D008231 |
| 199 | 1146-1151 | Disease | denotes | death | MESH:D003643 |